TSHA — Taysha Gene Therapies Share News
0.000.00%
Last trade - 00:00- $1.22bn
- $809.38m
- $9.77m
Brief: Taysha Gene Therapies Reports First Quarter 2022 Financial Results
Taysha Gene Therapies Inc expected to post a loss of $1.07 a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Blend Labs, Unifirst, Vertiv Holdings
U.S. RESEARCH ROUNDUP -A O Smith, Cerence, Comerica
Brief: Taysha Gene Therapies Q2 Loss Per Share Of $1.09
'Looking for upside in biotech? Start with gene therapy' - BTIG
U.S. RESEARCH ROUNDUP-Eli Lilly, Physicians Realty Trust, Welltower
Brief: Taysha Gene Therapies- Entered Into A License Agreement With Abeona Therapeutics Inc
U.S. STOCKS ON THE MOVE-Twitter, Caterpillar, Wells Fargo, Restaurant Brands
U.S. STOCKS ON THE MOVE-Abercrombie & Fitch, Boeing, Wells Fargo, Goldman Sachs
Shares of Taysha Gene Therapies gain 11% in Nasdaq debut
Brief: Taysha Gene Therapies Inc Shares Open 11.3% Above IPO Price In Debut on Nasdaq
Brief: Taysha Gene Therapies Announces Pricing Of Initial Public Offering
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 04:00 AM
Brief: Taysha Gene Therapies Estimates That Initial Public Offering Price Per Share Will Be Between $18.00 And $20.00